Joe Tippens was a 57-year-old Oklahoma man when his doctors told him he had small-cell lung cancer — one of the most aggressive and treatment-resistant forms of the disease. The cancer had spread to his neck, stomach, bladder, pancreas, and bones. He was given three months to live.
What happened next became one of the most discussed medical anecdotes of the past decade. At the suggestion of a veterinarian friend, Tippens began taking fenbendazole — a common antiparasitic medication used in veterinary medicine for decades — along with vitamin E succinate and curcumin. Within three months, follow-up scans showed no evidence of cancer anywhere in his body.
The Research That Followed
Tippens' story, which he shared publicly on his blog "My Cancer Story Rocks," sparked an enormous wave of anecdotal reports from cancer patients around the world, particularly in South Korea, where hundreds of patients began self-experimenting with fenbendazole protocols. South Korean medical journals began publishing case reports.
The scientific mechanism is plausible and well-studied. Fenbendazole and its close relative mebendazole are benzimidazole compounds that disrupt tubulin polymerization — the process cancer cells use to divide. A landmark 2008 paper published in Cancer Research showed that mebendazole was effective against brain tumor growth in animal models. A 2018 study in Scientific Reports found that fenbendazole had potent anti-cancer effects in human cell lines, disrupting both tubulin and glucose uptake — a double hit on cancer's core vulnerabilities.
Why Repurposed Drugs Threaten the Establishment
Fenbendazole costs a few dollars per dose. It has been used safely in humans and animals for 40 years. There is no patent. There is no billion-dollar clinical trial. And that is precisely why you will not see it discussed in mainstream oncology offices.
The United States spends over $200 billion per year on cancer treatments. Many of the most promising leads in oncology research involve repurposing cheap, off-patent drugs that have known safety profiles. The financial incentive to pursue these leads is almost nonexistent for pharmaceutical companies that cannot recoup research costs from a generic.
What Patients Are Doing
Thousands of patients in the United States are now adding fenbendazole to their cancer protocols — many with the quiet support of integrative physicians who have reviewed the literature. The standard protocol being discussed in patient communities involves fenbendazole combined with vitamin E succinate, curcumin, and berberine — the same general combination Tippens used.
No one is claiming fenbendazole is a cure. What the research community is saying is that it deserves rigorous clinical investigation — and that patients have the right to access it while that investigation is pending.
Key Takeaway: Fenbendazole's plausible anti-cancer mechanism, combined with a strong safety record and growing patient anecdotes, makes it one of the most compelling repurposed drug stories in modern medicine.